PMID- 31397525
OWN - NLM
STAT- MEDLINE
DCOM- 20200515
LR  - 20200515
IS  - 1440-1827 (Electronic)
IS  - 1320-5463 (Linking)
VI  - 69
IP  - 9
DP  - 2019 Sep
TI  - Proteogenomic discovery of cancer antigens: Neoantigens and beyond.
PG  - 511-518
LID - 10.1111/pin.12841 [doi]
AB  - Host T cells infiltrate the cancer lesion and contribute to patient survival. T 
      cells recognize antigen peptides displayed by the cancer cell human leukocyte 
      antigen (HLA) system. Cancer antigens constitute an essential element of T-cell 
      discrimination and play an indispensable role in anti-cancer responses. HLA 
      ligandome analysis directly and comprehensively detects the peptides that are 
      naturally presented by HLA of given cells, leading to discovery of cancer 
      antigens. A proteogenomic approach, which combines conventional proteomics with 
      genomic information, has further deciphered the landscape of the cancer HLA 
      ligandome. Neoantigens that arise from somatic mutations are arguably the major 
      type of peptides patient T cells recognize. Moreover, cancer cells present 
      peptides derived from alleged noncoding regions, which also elicit T-cell 
      responses thereby serving as cancer antigens. The diversity of newly discovered 
      antigen sources implies that T cells are capable of sensing a variety of genomic 
      aberrations in cancer.
CI  - (c) 2019 Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.
FAU - Kanaseki, Takayuki
AU  - Kanaseki T
AUID- ORCID: 0000-0001-7294-6880
AD  - Department of Pathology, Sapporo Medical University, Sapporo, Japan.
FAU - Tokita, Serina
AU  - Tokita S
AD  - Department of Pathology, Sapporo Medical University, Sapporo, Japan.
AD  - Sapporo Dohto Hospital, Sapporo, Japan.
FAU - Torigoe, Toshihiko
AU  - Torigoe T
AD  - Department of Pathology, Sapporo Medical University, Sapporo, Japan.
LA  - eng
GR  - JP18cm0106334/Japan Agency for Medical Research and Development/
GR  - JP18cm0106309/Japan Agency for Medical Research and Development/
GR  - 19H03490/Japan Society for the Promotion of Science/
GR  - 17H01540/Japan Society for the Promotion of Science/
PT  - Journal Article
PT  - Review
DEP - 20190809
PL  - Australia
TA  - Pathol Int
JT  - Pathology international
JID - 9431380
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (HLA Antigens)
RN  - 0 (Ligands)
RN  - 0 (Peptides)
RN  - 0 (RNA, Untranslated)
SB  - IM
MH  - Amino Acid Substitution
MH  - Antigen Presentation
MH  - Antigens, Neoplasm/genetics/*immunology
MH  - HLA Antigens/genetics/*immunology
MH  - Humans
MH  - Ligands
MH  - Mutation
MH  - Neoplasms/genetics/*immunology
MH  - Peptides/genetics/*immunology
MH  - *Proteogenomics
MH  - RNA, Untranslated/genetics
MH  - T-Lymphocytes/immunology
OTO - NOTNLM
OT  - HLA
OT  - cancer antigen
OT  - neoantigen
OT  - noncoding RNA
EDAT- 2019/08/10 06:00
MHDA- 2020/05/16 06:00
CRDT- 2019/08/10 06:00
PHST- 2019/05/20 00:00 [received]
PHST- 2019/07/07 00:00 [accepted]
PHST- 2019/08/10 06:00 [pubmed]
PHST- 2020/05/16 06:00 [medline]
PHST- 2019/08/10 06:00 [entrez]
AID - 10.1111/pin.12841 [doi]
PST - ppublish
SO  - Pathol Int. 2019 Sep;69(9):511-518. doi: 10.1111/pin.12841. Epub 2019 Aug 9.